Faculty
-
August 30, 2016
Robert Klitzman on EpiPen's Price Hike
With EpiPen price-gouging in the news, Columbia's School of Professional Studies Bioethics Program Director, Dr. Robert Klitzman, has a new op-ed in CNN about the ethical questions raised by drug companies' overcharging patients. It's a tangled story of the principles of medicine, the profit priorities of private companies, and the taxpayers' money that creates these innovations.
Read the full article at CNN.
Faculty
ERM part-time lecturer Naana Asare examines what Bank of America’s 2026 enforcement actions reveal about escalation, remediation and management accountability in financial crimes compliance.
Faculty
Health systems can only staff as fast as they can hire. AI agents are lifting the cap that talent acquisition headcount has put on hiring, and the effects show up well beyond recruiting.
Faculty
A Conversation with Matthias Kuhlmey on agentic advice, consumer control and the future of financial advice.
All News
